Revolution Medicines, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for cancers driven by RAS pathway alterations. The company’s research focuses on designing small-molecule inhibitors that directly or indirectly modulate key nodes in the RAS signaling cascade. By addressing historically “undruggable” targets such as mutant KRAS and SHP2, Revolution Medicines aims to bring precision medicines to patients whose tumors depend on RAS pathway dysregulation.
The company’s pipeline includes RMC-4630, an allosteric SHP2 inhibitor being evaluated across multiple RAS-pathway-driven tumor types, and RMC-6291, a selective KRAS(G12C) inhibitor designed to trap the mutant protein in its inactive state. Revolution Medicines has also advanced RMC-6236, a novel tri-complex inhibitor that simultaneously engages several RAS family members and regulatory proteins. These programs are supported by translational biomarker strategies to identify responsive patient populations and optimize combination approaches.
Founded in 2015 and headquartered in Redwood City, California, Revolution Medicines was established with backing from leading life-science investors. The company collaborates with academic institutions and biopharmaceutical partners to accelerate its clinical development efforts. Its research facilities and corporate offices in the San Francisco Bay Area serve as the hub for discovery, preclinical studies and clinical trial coordination, with additional clinical sites across the United States and select international locations.
The leadership team is led by President and Chief Executive Officer David S. King, Ph.D., who brings decades of oncology drug development experience. Under his guidance, Revolution Medicines has assembled a multidisciplinary team of drug hunters, structural biologists and clinical experts. Together, they aim to translate advances in RAS biology into differentiated therapies for patients with high unmet medical needs.
AI Generated. May Contain Errors.
